Integra LifeSciences to Buy Acclarent From Johnson & Johnson
December 13 2023 - 7:03AM
Dow Jones News
By Colin Kellaher
Integra LifeSciences Holdings has agreed to buy ear, nose and
throat (ENT) technology company Acclarent from a unit of Johnson
& Johnson for $275 million in cash.
Integra on Wednesday said the deal, which expands its portfolio
of ENT products and technologies, also includes an additional $5
million based on the achievement of certain regulatory
milestones.
Princeton, N.J., medical-technology company Integra said
Acclarent generated about $110 million in revenue in 2022.
Integra, which has forecast revenue of $1.54 billion to $1.55
billion for 2023, said it expects to complete the acquisition by
the second quarter of 2024.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
December 13, 2023 06:48 ET (11:48 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Integra LifeSciences (NASDAQ:IART)
Historical Stock Chart
From Apr 2024 to May 2024
Integra LifeSciences (NASDAQ:IART)
Historical Stock Chart
From May 2023 to May 2024
